These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

590 related items for PubMed ID: 11181341

  • 1. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [Abstract] [Full Text] [Related]

  • 2. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D, Zhong M, Mattoes H, Bui KQ, McNabb J, Nicolau DP, Quintiliani R, Nightingale CH.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A.
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [Abstract] [Full Text] [Related]

  • 4. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Coyle EA, Kaatz GW, Rybak MJ.
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
    [Abstract] [Full Text] [Related]

  • 5. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
    Jones ME, Visser MR, Klootwijk M, Heisig P, Verhoef J, Schmitz FJ.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I, Cars O.
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [Abstract] [Full Text] [Related]

  • 7. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
    Evans ME.
    Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
    Saravolatz L, Manzor O, Check C, Pawlak J, Belian B.
    J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
    [Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM, Laskowski R, Bjarnason J, Stewart C.
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
    Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Köhrer K, Schmitz FJ.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
    Sierra JM, Cabeza JG, Ruiz Chaler M, Montero T, Hernandez J, Mensa J, Llagostera M, Vila J.
    Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
    Johnson AP, Warner M, Livermore DM.
    Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA, Du X, Nicolau DP.
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [Abstract] [Full Text] [Related]

  • 16. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA, Alferova IV, Smirnova MV, Lubenko IY, Portnoy YA, Zinner SH.
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [Abstract] [Full Text] [Related]

  • 17. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
    Esposito S, Noviello S, Ianniello F.
    J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.